BeiGene opens a new office in Dubai expanding its presence in the MEA region
[ad_1]
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on the development and commercialization of innovative medicines worldwide, announced the first step in the company’s expansion in the Middle East region and North Africa (MENA) with the formal opening of its office in Dubai, United Arab Emirates.
The new office is located within the Dubai Science Park, part of TECOM Group PJSC, the region’s leading science-focused business community home to more than 450 clients and 5,500 professionals, and will host BeiGene’s administrative, commercial and medical colleagues.
Its opening ceremony was attended by high-level dignitaries, including His Excellency Awadh Seghayer Al Ketbi, Director General of Dubai Health Authority (DHA); Saleh Alhashimi, CEO of Dubai Health Insurance Corporation; Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of the TECOM Group; Mohammed Al-Kapany, CEO of BeiGene MENA; Jurij Petrin, Director of New Markets at BeiGene; and Professor Humaid Al-Shamsi, director of the Emirates Society of Oncology.
Founded in 2010, BeiGene has built one of the largest and most efficient oncology research teams in the world, with a portfolio of 17 approved assets (3 developed in-house) and a broad and deep portfolio focused on hematology and solid tumors with the potential to address 80 percent of the world’s problems. Cancers by incidence.
“Our expansion into the Middle East and North Africa region is an important step in our company’s ongoing global expansion and an opportunity to reinforce BeiGene’s commitment to bringing innovative, affordable and accessible medicines to more patients around the world.” .
saying Jurij Petrin, director of new market development at BeiGene.
“Dubai, recognized as the hub of regional and international trade in the UAE, is the ideal location for our first office in the region, signaling our growing presence in MENA and allowing us to better serve patients in the area”.
“We are delighted to announce our expansion to the United Arab Emirates, a pivotal location in the global fight against cancer. This move marks our commitment to MENA and we look forward to growing our talented team as we introduce innovative medicines to the world. region,”
saying Mohammed Al-Kapany, CEO, MENA.
“Our presence in Dubai Science Park, with its state-of-the-art facilities, will better support our team and our collaborations within the dynamic regional landscape to ensure that patients across the region can equally access our innovative therapies.”
Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of the TECOM Group, saying:
“Cancer remains a leading cause of death worldwide, affecting millions of people and their families each year. Greater collaboration across healthcare and biotechnology is essential to deliver breakthrough innovations that can improve survival rates and long-term outcomes for patients.
“Dubai Science Park is committed to making a significant impact in cancer care and fostering innovative partnerships within the healthcare and biotechnology communities to benefit patients around the world. We are aligned with the objectives of the Dubai Economic Agenda ‘D33’, the Dubai Research and Development Program and the ‘We, the UAE 2031’ vision to localize scientific advances that generate global impact, and we welcome BeiGene’s collaboration in our effort to deliver advances in healthcare around the world. world.”
Through modern laboratories, innovation centers, co-working spaces and a rich network of globally connected industry peers, the Dubai Science Park ecosystem enables and empowers R&D efforts that can unlock efficient and advances to improve patient outcomes in cancer cases.
Dubai Science Park is part of TECOM Group’s 10-district portfolio that includes Dubai Internet City, Dubai Media City, Dubai Studio City, Dubai Production City, Dubai Knowledge Park, Dubai International Academic City, Dubai Design District (d3) and Dubai Industrial City. .
About BeiGene
BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more affordable and accessible to cancer patients around the world. With a broad pipeline, we are accelerating the development of our diverse portfolio of novel therapies through our internal capabilities and collaborations. We are committed to radically improving access to medicines for many more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing and Cambridge, USA. For more information about BeiGeneplease visit www.beigene.com and follow us on LinkedIn and X (formerly known as Twitter).
News source: Dubai Press Office
[ad_2]
